outbreak
present
new
lifethreaten
diseas
aim
assess
potenti
effect
safeti
antivir
agent
children
electron
databas
incept
march
search
random
control
trial
clinic
control
trial
cohort
studi
intervent
antivir
agent
children
less
year
age
total
studi
indirect
evid
patient
includ
risk
bia
studi
moder
high
gener
effect
safeti
antivir
agent
children
uncertain
adult
lopinavirritonavir
effect
mortal
risk
ratio
rr
confid
interv
ci
probabl
neg
pcr
test
ci
arbidol
benefit
probabl
neg
pcr
test
ci
hydroxychloroquin
associ
increas
probabl
neg
pcr
result
ci
adult
sar
interferon
associ
reduc
corticosteroid
dose
weight
mean
differ
wmd
g
ci
effect
mortal
ci
ribavirin
reduc
mortal
ci
associ
high
risk
sever
advers
reaction
oseltamivir
effect
mortal
ci
ribavirin
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
medrxiv
preprint
combin
interferon
also
effect
adult
mer
associ
advers
reaction
evid
show
effect
antivir
agent
children
clinic
efficaci
exist
antivir
agent
still
uncertain
suggest
clinic
routin
use
antivir
children
except
clinic
trial
field
identifi
studi
may
miss
search
strategi
also
peer
review
extern
specialist
systemat
search
combin
mesh
free
word
keyword
term
medlin
includ
novel
coronaviru
coronaviru
antivir
agent
antivir
ribavirin
interferon
oseltamivir
remdesivir
lopinavir
ritonavir
lpvr
deriv
detail
search
strategi
found
supplementari
materi
primarili
search
studi
children
less
year
age
diagnos
made
restrict
gender
race
geograph
locat
set
includ
random
control
trial
rct
clinic
control
trial
cct
cohort
studi
compar
effect
safeti
antivir
agent
includ
limit
ifn
oseltamivir
lpvr
rbv
hcq
remdesivir
placebo
compar
combin
antivir
agent
symptomat
treatment
symptomat
treatment
alon
studi
compar
differ
type
differ
administr
mode
antivir
agent
also
includ
vitro
studi
anim
experi
basic
research
exclud
duplic
articl
written
languag
english
chines
confer
abstract
studi
full
text
could
retriev
data
miss
also
exclud
primari
outcom
mortal
risk
seriou
advers
effect
defin
hemolyt
anemia
bradycardia
side
effect
cardiovascular
system
druginduc
liver
injuri
secondari
outcom
includ
probabl
neg
pcr
test
defin
rate
neg
pcr
discharg
hospit
receiv
antivir
agent
differ
studi
mean
reduct
dose
corticosteroid
remiss
main
clinic
symptom
risk
acut
respiratori
distress
syndrom
ard
durat
diseas
defin
durat
day
total
stay
symptom
onset
recoveri
probabl
admiss
intens
care
unit
icu
advers
reaction
reason
exclus
inelig
studi
record
process
studi
select
document
use
prisma
flow
diagram
use
discrep
discuss
solv
third
research
q
zhou
reason
exclus
inelig
studi
record
process
studi
select
document
use
prisma
flow
diagram
four
research
q
shi
x
wang
q
zhou
j
liao
extract
data
independ
pair
predetermin
form
disagr
resolv
consensu
extract
follow
data
basic
inform
particip
baselin
characterist
inclusionexclus
criteria
detail
intervent
control
strategi
outcom
dichotom
data
number
event
total
particip
per
group
continu
data
mean
standard
deviat
sd
number
total
particip
per
group
two
research
yu
z
wang
independ
assess
potenti
bia
includ
studi
discrep
resolv
discuss
consensu
third
research
lu
rct
use
cochran
riskofbia
rob
assess
tool
consist
seven
domain
random
sequenc
gener
alloc
conceal
blind
particip
personnel
blind
outcom
assess
incomplet
outcom
data
select
outcom
report
bia
grade
potenti
sourc
bia
low
unclear
high
includ
cct
use
robinsi
tool
consist
seven
domain
bia
due
confound
bia
select
particip
bia
classif
intervent
bia
due
departur
intend
intervent
bia
due
miss
data
bia
outcom
measur
bia
select
report
risk
type
bia
grade
low
moder
seriou
critic
inform
rob
robinsi
overal
risk
bia
within
studi
base
result
individu
domain
cohort
studi
use
newcastleottawa
scale
no
consist
three
domain
select
exposur
compar
assess
outcom
maximum
score
nine
score
seven
grade
high
qualiti
less
seven
score
low
qualiti
perform
metaanalys
outcom
data
suffici
compat
outcom
heterogen
data
qualit
synthesi
done
process
data
accord
cochran
handbook
use
randomeffect
model
dichotom
data
calcul
risk
ratio
rr
confid
interv
ci
continu
data
calcul
weight
mean
differ
wmd
ci
twosid
p
valu
consid
statist
signific
analys
perform
stata
softwar
stata
corp
llc
miss
sd
standard
error
se
convert
sd
se
present
miss
estim
sd
p
valu
ci
statist
heterogen
assess
use
chisquar
statist
p
consid
consist
statist
signific
heterogen
statist
indic
substanti
heterogen
detect
heterogen
perform
subgroup
analys
rout
dose
frequenc
administr
antivir
sensit
analys
exclud
studi
lowqual
high
risk
bia
exclud
studi
mean
sd
imput
miss
data
explor
reason
public
bia
assess
examin
symmetri
funnelplot
assess
qualiti
evid
use
grade
recommend
assess
develop
evalu
grade
approach
classifi
evid
qualiti
high
moder
low
low
also
produc
summari
find
tabl
direct
evid
rct
start
high
qualiti
evid
observ
studi
low
qualiti
next
step
qualiti
downgrad
five
differ
reason
studi
limit
consist
effect
imprecis
indirect
public
bia
upgrad
three
reason
larg
magnitud
effect
doserespons
relat
plausibl
confound
bias
identifi
refer
databas
six
record
addit
search
total
record
exclud
duplic
screen
titl
abstract
full
text
direct
evid
children
found
final
total
studi
six
rct
cohort
studi
patient
indirect
evid
includ
figur
studi
publish
sampl
size
rang
seven
studi
studi
sar
three
studi
mer
anoth
studi
cai
found
temporari
remov
condit
therefor
includ
risk
bia
includ
three
rct
high
perform
alloc
conceal
blind
patient
clinician
three
rct
low
risk
bia
half
cohort
studi
high
risk
bia
main
reason
lack
control
import
factor
would
influenc
primari
studi
result
lack
long
enough
followup
outcom
occur
inadequ
outcom
ascertain
studi
characterist
risk
bia
illustr
tabl
result
metaanalysi
type
antivir
agent
shown
tabl
detail
primari
data
retriev
studi
found
supplementari
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
four
cohort
studi
total
patient
report
effect
safeti
intramuscular
subcutan
inject
ifn
adult
patient
sar
result
show
ifn
therapi
decreas
dose
corticosteroid
dose
g
ci
promot
remiss
radiograph
abnorm
statist
signific
differ
found
mortal
ci
figur
obviou
advers
reaction
report
four
studi
qualiti
evid
low
one
cohort
studi
total
patient
statist
differ
risk
death
ci
figur
addit
use
rbv
associ
increas
risk
advers
reaction
includ
anemia
ci
lowqual
two
cohort
studi
total
patient
report
effect
safeti
combin
rbv
ifn
adult
patient
mer
result
show
combin
therapi
rbv
ifn
could
increas
mean
reduct
figur
two
group
one
studi
total
patient
addit
statist
signific
differ
incid
advers
reaction
ci
hcq
therapi
control
group
overal
qualiti
evid
low
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
rapid
review
identifi
total
studi
direct
evid
effect
safeti
antivir
agent
children
avail
base
analysi
indirect
evid
adult
patient
low
lowqual
evid
indic
lpvr
arbidol
hydroxychloroquin
effect
adult
patient
sar
mer
low
lowqual
evid
indic
lpvr
ifn
rbv
oseltamivir
clinic
effect
mortal
corticosteroid
dose
main
outcom
certain
medic
lpvr
rbv
like
lead
advers
reaction
gastrointestin
reaction
abnorm
liver
function
anemia
bradycardia
hypoxemia
result
antivir
similar
identifi
systemat
review
among
patient
use
hcq
effect
clinic
recoveri
publish
review
found
hcq
benefit
probabl
viral
load
disappear
previou
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
due
retract
philipp
trial
hcq
includ
studi
small
sampl
size
draw
robust
conclus
ifn
benefit
mortal
effect
differ
result
line
anoth
recent
rapid
review
rbv
oseltamivir
shown
effect
treat
adult
sar
use
rbv
even
relat
high
risk
seriou
side
effect
oseltamivir
prolong
durat
diseas
result
also
observ
recent
previou
systemat
review
one
studi
demonstr
concentr
rbv
requir
effect
inhibit
activ
sarscov
merscov
beyond
clinic
accept
rang
routin
use
drug
would
effect
impos
great
socioeconom
public
health
clinic
burden
affect
countri
region
especi
lowand
middleincom
countri
therefor
prioriti
given
research
implement
agent
promis
outcom
studi
knowledg
first
systemat
comprehens
rapid
review
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
unabl
perform
quantit
analysi
aspect
antivir
major
obstacl
clear
interpret
result
review
third
specif
urgenc
pheic
studi
protocol
regist
prospect
regist
systemat
review
platform
suggest
action
basi
studi
first
highqual
clinic
research
carri
time
effect
manner
follow
random
control
bind
principl
evidencebas
medicin
tri
adopt
object
repres
outcom
evalu
unbias
research
result
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
ensur
second
health
worker
need
highqual
unbias
evidencebas
recommend
guid
clinic
practic
health
worker
accumul
clinic
experi
encourag
interpret
evid
profession
cooper
research
avoid
conflict
interest
thu
reduc
possibl
harm
impact
children
third
health
polici
decis
made
base
best
avail
evid
make
full
use
limit
resourc
make
decis
valid
ration
base
uptod
scientif
knowledg
conclus
direct
evid
antivir
agent
children
far
low
lowqual
indirect
evid
indic
antivir
agent
effect
reduc
mortal
effect
safeti
antivir
children
uncertain
therefor
suggest
routin
use
agent
treatment
children
except
clinic
trial
thorough
ethic
assess
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
wang
lu
vi
manuscript
write
author
vii
final
approv
manuscript
author
thank
jann
estil
institut
global
health
univers
geneva
provid
guidanc
comment
review
thank
author
wonder
author
conflict
interest
declar
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
apr
avail
onlin
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
explod
tree
ti
ab
kw
ti
ab
kw
novel
coronaviru
ti
ab
kw
coronaviru
ti
ab
kw
novel
cov
ti
ab
kw
ti
ab
kw
ti
ab
kw
coronaviru
ti
ab
kw
coronaviru
diseas
ti
ab
kw
ti
ab
kw
wuhancov
ti
ab
kw
wuhan
coronaviru
ti
ab
kw
wuhan
seafood
market
pneumonia
viru
ti
ab
kw
middl
east
respiratori
syndrom
ti
ab
kw
mer
ti
ab
kw
merscov
ti
ab
kw
sever
acut
respiratori
syndrom
ti
ab
kw
sar
ti
ab
kw
sarscov
ti
ab
kw
sarsrel
ti
ab
kw
sarsassoci
ti
ab
kw
mesh
descriptor
antivir
agent
explod
tree
antivir
ti
ab
kw
ribavirin
ti
ab
kw
virazol
ti
ab
kw
interferon
ti
ab
kw
remdesivir
ti
ab
kw
ti
ab
kw
oseltamivir
ti
ab
kw
lopinavir
ti
ab
kw
ritonavir
ti
ab
kw
kaletra
ti
ab
kw
lpvr
ti
ab
kw
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
effect
ribavirin
crude
death
rate
number
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ard
acut
respiratori
distress
syndrom
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
downgrad
one
level
sampl
size
less
optim
inform
sampl
oi
result
metaanalysi
indic
lopinavirritonavir
effect
mortal
adult
risk
ratio
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
addit
record
identifi
sourc
n
record
duplic
remov
n
record
screen
n
fulltext
articl
assess
elig
n
fulltext
articl
exclud
fulltext
retriev
case
reportsseri
review
protocol
studi
includ
qualit
synthesi
n
studi
includ
quantit
synthesi
metaanalysi
n
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
